AX-2025-019930

Mazdutide · 6 mg declared · Shanghai Wibson Biotechnology Co., Ltd. · lot SWB-2505-Y5355

MARGINALPURITY ONLY

Report ID: AX-2025-019930
Compound: Mazdutide
Compound class: Incretin analogues and co-agonists
Supplier: SWB — Shanghai Wibson Biotechnology Co., Ltd.
Batch / lot: SWB-2505-Y5355
Declared label claim: 6mg
Laboratory: Janoshik Analytical
Assay date: 27 Oct 2025
Submitted: 21 Nov 2025
Quarter: 2025-Q4
Submitter: r.kjaer
Sample provenance: Supplier-supplied

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.25	% area	≥ 96.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.75	% area	≤ 3.5	PASS
Largest single impurity	RP-HPLC — oxidised Met (+16 Da)	0.81	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	88.80	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	87.25	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	6.95	mg	6 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	6.064	mg	6 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	101.1	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	3.37	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	7.31	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.52	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Faint haze, clearing on standing	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	2.53	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	19.36	min	19.42 ± 0.50 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.08	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	69,115	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Aib2]-diastereomer	0.70	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 69,115, and skew follows the reported asymmetry factor of 1.08. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.81 % impurity against a 98.25 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Mazdutide — main peak	19.36	4,775,255	98.25	—
2	oxidised Met (+16 Da)	18.66	39,369	0.81	+15.995
3	des-Aib2 analogue	18.97	20,413	0.42	-85.053
4	trifluoroacetyl adduct (+96 Da)	20.26	10,207	0.21	+95.982
5	truncated (4-39)	17.62	8,749	0.18	-315.169
6	[D-Aib2]-diastereomer	19.15	6,318	0.13	0.000
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.37
Counter-ion (TFA)	ion chromatography	7.31
Residual solvent + inorganic residue	estimated	0.52
Total peptide content	by difference	88.80
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.64	98.25	divergence +0.37 pp vs batch median
Total impurities (% area)	1.36	1.75
Largest single impurity (% area)	0.94	0.81
Water (%)	not stated	3.37
Counter-ion (%)	4.5	7.31
Peptide content (%w/w)	91.4	88.80
Endotoxin (EU/mg)	0.44	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 8 d) → assay. Submitter did not handle the vial.
Assay date: 27 Oct 2025
Submitted to the index: 21 Nov 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot SWB-2505-Y5355 n=8

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-019931	SWB-2505-Y5355	VendorInvestigate	2025-Q4	98.28	2.90	—	Buyer-sourced	1	MARGINAL
AX-2025-019932	SWB-2505-Y5355	Medutest	2025-Q4	97.88	3.17	90.2	Supplier-supplied	1	MARGINAL
AX-2025-019933	SWB-2505-Y5355	Janoshik	2025-Q4	98.57	2.95	—	Supplier-supplied	1	FAIL
AX-2025-019934	SWB-2505-Y5355	Medutest	2025-Q4	98.42	3.35	97.1	Supplier-supplied	1	FAIL
AX-2025-019935	SWB-2505-Y5355	PeptideMeter	2025-Q4	97.88	3.44	—	Buyer-sourced	1	MARGINAL
AX-2025-019936	SWB-2505-Y5355	Janoshik	2025-Q4	98.10	3.06	91.4	Supplier-supplied	1	MARGINAL
AX-2025-019937	SWB-2505-Y5355	Medutest	2025-Q4	98.58	3.51	—	Supplier-supplied	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Mazdutide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042560	ERP	ERP-2603-D7882	VendorInvestigate	2026-Q2	97.28	3.81	104.1	Buyer-sourced	2	MARGINAL
AX-2026-043117	SSA	SSA-2605-G6781	Janoshik	2026-Q2	99.23	3.67	90.4	Supplier-supplied	1	MARGINAL
AX-2026-043118	SSA	SSA-2605-G6781	Medutest	2026-Q2	98.29	2.65	88.7	Buyer-sourced	2	MARGINAL
AX-2026-042562	ERP	ERP-2603-D7882	Janoshik	2026-Q2	97.46	4.39	102.6	Supplier-supplied	2	MARGINAL
AX-2026-042561	ERP	ERP-2603-D7882	PeptideMeter	2026-Q2	97.94	4.04	97.5	Supplier-supplied	2	MARGINAL
AX-2026-043115	SSA	SSA-2605-G6781	PeptideMeter	2026-Q2	98.45	2.48	97.0	Buyer-sourced	1	MARGINAL
AX-2026-043119	SSA	SSA-2605-G6781	Janoshik	2026-Q2	99.28	2.75	—	Supplier-supplied	1	MARGINAL
AX-2026-043120	SSA	SSA-2605-G6781	PeptideMeter	2026-Q2	98.74	3.24	104.0	Supplier-supplied	1	MARGINAL

Other recent SWB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042461	Kisspeptin-10	SWB-2603-D6238	Janoshik	2026-Q3	98.35	4.65	96.5	Supplier-supplied	3	FAIL
AX-2026-042479	Melanotan II	SWB-2603-A5707	Janoshik	2026-Q3	99.16	3.67	94.5	Supplier-supplied	1	MARGINAL
AX-2026-042481	Melanotan II	SWB-2603-A5707	Medutest	2026-Q3	98.95	3.37	90.8	Supplier-supplied	1	MARGINAL
AX-2026-042460	Kisspeptin-10	SWB-2603-D6238	Kestrel	2026-Q3	99.55	4.21	90.8	Supplier-supplied	3	MARGINAL
AX-2026-042483	Melanotan II	SWB-2603-A5707	Janoshik	2026-Q3	99.38	3.73	107.2	Supplier-supplied	1	MARGINAL
AX-2026-042398	Semaglutide	SWB-2602-X5278	Nordanalyt	2026-Q3	99.08	4.48	—	Supplier-supplied	1	MARGINAL
AX-2026-042399	Semaglutide	SWB-2602-X5278	Janoshik	2026-Q3	98.56	3.82	—	Supplier-supplied	1	MARGINAL
AX-2026-042499	BPC-157	SWB-2607-Y5787	Kestrel	2026-Q3	99.93	4.25	94.4	Supplier-supplied	0	PASS